Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention.

kappa-Opioid receptor agonists (niravoline) or nonpeptide antidiuretic hormone (ADH) V2 receptor antagonists (OPC-31260) possess aquaretic activity in cirrhosis; however, there is no information concerning the effects induced by the chronic administration of these drugs under this condition. To compare the renal and hormonal effects induced by the long-term oral administration of niravoline, OPC-31260, or vehicle, urine volume, urinary osmolality, sodium excretion, and urinary excretion of aldosterone (ALD) and ADH were measured in basal conditions and for 10 days after the daily oral administration of niravoline, OPC-31260, or vehicle to cirrhotic rats with ascites and water retention. Creatinine clearance, serum osmolality, ADH mRNA expression, and systemic hemodynamics were also measured at the end of the study. Niravoline increased water excretion, peripheral resistance, serum osmolality, and sodium excretion and reduced creatinine clearance, ALD and ADH excretion, and mRNA expression of ADH. OPC-31260 also increased water metabolism and sodium excretion and reduced urinary ALD, although the aquaretic effect was only evident during the first 2 days, and no effects on serum osmolality, renal filtration, and systemic hemodynamics were observed. Therefore, both agents have aquaretic efficacy, but the beneficial therapeutic effects of the long-term oral administration of niravoline are more consistent than those of OPC-31260 in cirrhotic rats with ascites and water retention.

[1]  T. Berl,et al.  Hyponatremia in cirrhosis: From pathogenesis to treatment , 1998, Hepatology.

[2]  W. Jiménez,et al.  Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion , 1998, Hepatology.

[3]  R. Moreau,et al.  Renal and haemodynamic responses to a novel kappa opioid receptor agonist, niravoline (RU 51,599), in rats with cirrhosis , 1996, Journal of gastroenterology and hepatology.

[4]  D. Bichet,et al.  Systemic and regional hemodynamic and biological effects of a new kappa-opioid agonist, niravoline, in healthy volunteers. , 1996, The Journal of pharmacology and experimental therapeutics.

[5]  D. Brooks,et al.  kappa-Opioid agonist inhibition of osmotically induced AVP release: preferential action at hypothalamic sites. , 1996, The American journal of physiology.

[6]  Asmar.  Therapeutic Efficacy , 2020, Definitions.

[7]  W. Jiménez,et al.  Aquaretic effect of the kappa-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention. , 1995, Gastroenterology.

[8]  K. Okada,et al.  Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. , 1994, Kidney international.

[9]  W. Jiménez,et al.  Antidiuretic Hormone and the Pathogenesis of Water Retention in Cirrhosis with Ascites , 1994, Seminars in liver disease.

[10]  Y. Yamamura,et al.  Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. , 1993, The Journal of clinical investigation.

[11]  D. Kapusta,et al.  Central kappa opioid receptor-evoked changes in renal function in conscious rats: participation of renal nerves. , 1993, The Journal of pharmacology and experimental therapeutics.

[12]  W. Jiménez,et al.  Impaired responsiveness to angiotensin II in experimental cirrhosis: Role of nitric oxide , 1993, Hepatology.

[13]  K. Okada,et al.  Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats. , 1993, Kidney international.

[14]  R. Schrier,et al.  Vasopressin Gene Expression in Rats with Experimental Cirrhosis , 1993, Hepatology.

[15]  Yoshitaka Yamamura,et al.  Characterization of a novel aquaretic agent, OPC‐31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist , 1992, British journal of pharmacology.

[16]  D. Carter,et al.  Vasopressin and oxytocin gene expression in rat testis. , 1991, Endocrinology.

[17]  S. Jouquey,et al.  Kappa agonists and vasopressin secretion. , 1990, Hormone research.

[18]  M. Imai,et al.  Mechanism of diuretic action of U-62,066E, a κ opioid receptor agonist , 1989 .

[19]  K. Lenz,et al.  Beneficial effect of 8-ornithin vasopressin on renal dysfunction in decompensated cirrhosis. , 1989, Gut.

[20]  M. Imai,et al.  Mechanism of diuretic action of U-62,066E, a kappa opioid receptor agonist. , 1989, European journal of pharmacology.

[21]  V. Arroyo,et al.  Temporal relationship between the impairment of free water excretion and antidiuretic hormone hypersecretion in rats with experimental cirrhosis. , 1987, Gastroenterology.

[22]  R. Schrier,et al.  Sodium excretion in advanced cirrhosis: Effect of expansion of central blood volume and suppression of plasma aldosterone , 1986, Hepatology.

[23]  R. Zerbe,et al.  Diuresis and suppression of vasopressin by kappa opioids: comparison with mu and delta opioids and clonidine. , 1985, The Journal of pharmacology and experimental therapeutics.

[24]  C. Dani,et al.  Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. , 1985, Nucleic acids research.

[25]  J. Bruix,et al.  Temporal relationship between hyperaldosteronism, sodium retention and ascites formation in rats with experimental cirrhosis , 1985, Hepatology.

[26]  L. Kinter,et al.  Critical differences between species in the in vivo and in vitro renal responses to antidiuretic hormone antagonists. , 1983, Progress in brain research.

[27]  J. H. Ludens,et al.  Studies on the nature and mechanism of the diuretic activity of the opioid analgesic ethylketocyclazocine. , 1982, The Journal of pharmacology and experimental therapeutics.

[28]  M. Manning,et al.  Vasopressin analogs that antagonize antidiuretic responses by rats to the antidiuretic hormone. , 1981, Science.